Ascendis Pharma Files 6-K for September 2025
Ticker: ASND · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1612042
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K on 9/30/25, confirming 20-F filings and providing Danish address.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on September 30, 2025, to report information as a foreign private issuer. The filing indicates that the company will file annual reports under Form 20-F. It also includes information about the company's principal executive offices located in Hellerup, Denmark.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Ascendis Pharma's status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain material non-public information that would typically impact risk.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 20250930 (date) — Filing Date
- Tuborg Boulevard 12 DK-2900 Hellerup Denmark (location) — Principal executive offices
- Form 20-F (document) — Annual Report Filing Type
- Form 6-K (document) — Filing Type
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information as a foreign private issuer for the month of September 2025.
Which form does Ascendis Pharma A/S file for its annual reports?
Ascendis Pharma A/S files its annual reports under cover of Form 20-F.
Where are Ascendis Pharma A/S's principal executive offices located?
Ascendis Pharma A/S's principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
What is the Commission File Number for Ascendis Pharma A/S?
The Commission File Number for Ascendis Pharma A/S is 001-36815.
Does this filing indicate submission of Form 6-K in paper format?
The filing includes check boxes for submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) and Rule 101(b)(7), but it does not indicate that the company is actually submitting in paper format.
Filing Stats: 396 words · 2 min read · ~1 pages · Grade level 15.9 · Accepted 2025-09-30 16:02:17
Key Financial Figures
- $97.45 — cash consideration of approximately USD $97.45 per share, based on the DKK-USD exchang
Filing Documents
- d76893d6k.htm (6-K) — 12KB
- d76893dex11.htm (EX-1.1) — 1199KB
- g76893dsp174.jpg (GRAPHIC) — 3KB
- g76893dsp175.jpg (GRAPHIC) — 3KB
- g76893dsp177.jpg (GRAPHIC) — 3KB
- g76893dsp178.jpg (GRAPHIC) — 3KB
- g76893dsp179.jpg (GRAPHIC) — 3KB
- g76893dsp180.jpg (GRAPHIC) — 5KB
- g76893dsp_24a.jpg (GRAPHIC) — 4KB
- g76893dsp_25a.jpg (GRAPHIC) — 8KB
- g76893dsp_25b.jpg (GRAPHIC) — 3KB
- g76893dsp_26a.jpg (GRAPHIC) — 6KB
- g76893dsp_33a.jpg (GRAPHIC) — 4KB
- g76893dsp_33b.jpg (GRAPHIC) — 8KB
- g76893dsp_34a.jpg (GRAPHIC) — 3KB
- g76893dsp_34b.jpg (GRAPHIC) — 6KB
- g76893page43.jpg (GRAPHIC) — 4KB
- g76893page44a.jpg (GRAPHIC) — 8KB
- g76893page44b.jpg (GRAPHIC) — 3KB
- g76893page45.jpg (GRAPHIC) — 6KB
- 0001193125-25-224999.txt ( ) — 1331KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: September 30, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer